Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFRA3 | O60609 | 5/20 | 0.53 |
| ▸ | GFRA2 | O00451 | 4/20 | 0.53 |
| ▸ | IDO1 | P14902 | 4/20 | 0.46 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | GFRA1 | P56159 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746652 | 0.84 | GFRA3 (0.63) | GFRA3GFRA2IDO1RETFFAR1 | |
| SCHEMBL1747049 | 0.82 | GFRA3 (0.58) | GFRA3GFRA2IDO1RETFFAR1 | |
| SCHEMBL8530467 | 0.81 | IDO1 (0.50) | GFRA3GFRA2IDO1RETFFAR1 | |
| SCHEMBL1745124 | 0.80 | GFRA3 (0.52) | GFRA3GFRA2RETFFAR1 | |
| SCHEMBL12017975 | 0.78 | IDO1 (0.61) | GFRA3GFRA2IDO1FFAR1GPR84 | |
| SCHEMBL18616585 | 0.78 | PPARD (0.44) | FFAR1PRMT5WDR77 | |
| SCHEMBL1746643 | 0.78 | IDO1 (0.50) | GFRA3GFRA2IDO1RETFFAR1 | |
| SCHEMBL31360588 | 0.78 | IDO1 (0.50) | GFRA3GFRA2IDO1FFAR1 | |
| SCHEMBL18618135 | 0.76 | PPARD (0.48) | PRMT5WDR77 | |
| SCHEMBL1746725 | 0.76 | GFRA3 (0.50) | GFRA3GFRA2RETFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | GFRA3 412/4885GFRA2 338/4885IDO1 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.